Lecanemab

The UK health regulator has ruled out offering a much-anticipated Alzheimer drug to patients on the National Health Service after concluding the costs of the drug outweighed its benefits. But having passed safety tests, 'Lecanemab' could still be available privately for those able to pay tens of thousands of dollars per year for private treatment. Here's Stuart Smith with more from London.